Navarro-Compán, VictoriaNavarro-Sarabia, Federico2012-10-012012-10-012011-07-15Navarro-Compán V, Navarro-Sarabia F. Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis. Clinical Medicine Insights: Therapeutics 2011 3 (195-203)1179-559Xhttp://hdl.handle.net/10668/505Biological therapies have been a major advance in RA treatment. However, remission or response is not achieved in all patients. Therefore, new drugs seem necessary. Most recent trials have focused in the development of three different groups of molecules: those against commercialized targets but minimizing side effects or improving administration, others molecules against new targets, and a third group including small molecules. Some of them have been shown to be clinically efficacious and safe in RA patients, including: two new anti-TNF􀁁 therapies (golimumab and certolizumab pegol), three anti-CD (ocrelizumab, ofatumumab and a SMIP), subcutaneous abatacept, anti-IL17 therapy, tasocitinib and fostamatinib disodium. Therefore, a wide spectrum of new RA therapeutics are promising, but more studies are necessary to confirm these results.enNew targetsMonoclonal antibodiesSmall moleculesRheumatoid arthritisEfficacySafetyNuevos objetivosAnticuerpos monoclonalesMoléculas pequeñasArtritis reumatoideEficaciaSeguridadMedical Subject Headings::Diseases::Musculoskeletal Diseases::Rheumatic Diseases::Arthritis, RheumatoidMedical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::CytokinesMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Complementary Therapiesreview articleopen access10.4137/CMT.S3781